What's in Daiichi Sankyo Co., Ltd.'s pipeline?

Daiichi Sankyo Co., Ltd. has 20 drugs in our index: 2 marketed, 0 filed, 6 in Phase 3, 5 in Phase 2, 7 in Phase 1.

Which companies overlap with Daiichi Sankyo Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Amgen, Bayer, Hoffmann-La Roche, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/daiichi-sankyo-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Daiichi Sankyo Co., Ltd. — Portfolio Competitive Intelligence Brief

Daiichi Sankyo Co., Ltd. pipeline: 2 marketed, 0 filed, 6 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 6 Phase 3 5 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
olmesartan medoxomil and a diuretic	olmesartan medoxomil and a diuretic	marketed	Angiotensin II receptor blocker (ARB) + diuretic combination	AT1 receptor (angiotensin II type 1 receptor)	Cardiovascular
olmesartan medoxomil and a CCB	olmesartan medoxomil and a CCB	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor; L-type voltage-gated calcium channel	Cardiovascular
CS-8958	CS-8958	phase 3	Neuraminidase inhibitor	Influenza neuraminidase	Infectious Disease
CS-3150	CS-3150	phase 3	Mineralocorticoid receptor antagonist	Mineralocorticoid receptor (MR)	Cardiovascular
Alendronate sodium hydrate	Alendronate sodium hydrate	phase 3	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite	Bone metabolism / Osteoporosis
DS-5565	DS-5565	phase 3	Selective sodium channel inhibitor	Voltage-gated sodium channels (Nav)	Neurology / Pain Management
DS-8201a	DS-8201a	phase 3	HER2-targeted antibody-drug conjugate	HER2 (human epidermal growth factor receptor 2)	Oncology
DU-176b (edoxaban)	DU-176b (edoxaban)	phase 3	Direct Factor Xa inhibitor	Factor Xa	Cardiovascular

Therapeutic area mix

Cardiovascular · 4
Oncology · 2
Bone metabolism / Osteoporosis · 1
Infectious Disease · 1
Neurology / Pain Management · 1
Psychiatry · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 4 shared drug classes
Amgen · 2 shared drug classes
Bayer · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Universitaire Ziekenhuizen KU Leuven · 2 shared drug classes
AstraZeneca · 1 shared drug class
Aarhus University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Daiichi Sankyo Co., Ltd.:

Cite this brief

Drug Landscape (2026). Daiichi Sankyo Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/daiichi-sankyo-co-ltd. Accessed 2026-05-16.